CIK 0001894562 · <br>Emerging growth company
Prime Medicine, Inc.
Sign in to watch- Ticker
- PRME
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-465-0013
- Business address
- 60 FIRST ST., CAMBRIDGE, MA, 02141
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-08-01 | Foster-Cheek Kaye I Director | Grant or award · Stock Option (right to buy) | +9,006 | 9,006 | ||
| 2025-08-01 | Foster-Cheek Kaye I Director | Returned to the company · Stock Option (right to buy) | −39,062 | 0 | ||
| 2025-08-01 | Foster-Cheek Kaye I Director | Grant or award · Stock Option (right to buy) | +39,062 | 39,062 | ||
| 2025-08-01 | Foster-Cheek Kaye I Director | Returned to the company · Stock Option (right to buy) | −45,000 | 0 | ||
| 2025-08-01 | Foster-Cheek Kaye I Director | Grant or award · Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2025-08-01 | Chung Wendy Director | Returned to the company · Stock Option (right to buy) | −13,510 | 0 | ||
| 2025-08-01 | Chung Wendy Director | Grant or award · Stock Option (right to buy) | +13,510 | 13,510 | ||
| 2025-08-01 | Chung Wendy Director | Returned to the company · Stock Option (right to buy) | −9,006 | 0 | ||
| 2025-08-01 | Chung Wendy Director | Grant or award · Stock Option (right to buy) | +9,006 | 9,006 | ||
| 2025-08-01 | Chung Wendy Director | Returned to the company · Stock Option (right to buy) | −39,062 | 0 | ||
| 2025-08-01 | Chung Wendy Director | Grant or award · Stock Option (right to buy) | +39,062 | 39,062 | ||
| 2025-08-01 | Chung Wendy Director | Returned to the company · Stock Option (right to buy) | −45,000 | 0 | ||
| 2025-08-01 | Chung Wendy Director | Grant or award · Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2025-08-01 | Cahill Thomas Director | Returned to the company · Stock Option (right to buy) | −39,062 | 0 | ||
| 2025-08-01 | Cahill Thomas Director | Grant or award · Stock Option (right to buy) | +39,062 | 39,062 | ||
| 2025-08-01 | Cahill Thomas Director | Returned to the company · Stock Option (right to buy) | −45,000 | 0 | ||
| 2025-08-01 | Cahill Thomas Director | Grant or award · Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2025-08-01 | Reine Allan Chief Executive Officer | Returned to the company · Stock Option (right to buy) | −850,000 | 0 | ||
| 2025-08-01 | Reine Allan Chief Executive Officer | Grant or award · Stock Option (right to buy) | +850,000 | 850,000 | ||
| 2025-08-01 | Alenson Carman See Remarks | Returned to the company · Stock Option (right to buy) | −16,083 | 0 |
Page 3 of 13 · 241 trades